This research described in this proposal can be segmented into four distinct parts. These include: (a) the development of a synthetic protocol which will permit large scale, enantioselective syntheses of the antiviral agent, 3'-thia-2'-deoxycytidine (BCH-189); (b) the development of a synthetic protocol which will permit large scale, enantioselective syntheses of the anitviral agent, 5-fluoro-3'-thia-2'-deoxycytidine (DLS-022); (c) the preparation and evaluation of a large variety of analogues of 3'-thia-2'deoxycytidine; (d) the preparation and evaluation of other heterocyclic nucleoside analogues, including dioxolanes, dithiolanes, oxathiolanes, imidazolanes, oxazolanes and thiazolanes.

Agency
National Institute of Health (NIH)
Institute
National Institute of Allergy and Infectious Diseases (NIAID)
Type
Research Project (R01)
Project #
5R01AI031827-02
Application #
3146832
Study Section
AIDS and Related Research Study Section 4 (ARRD)
Project Start
1991-07-01
Project End
1994-06-30
Budget Start
1992-07-01
Budget End
1993-06-30
Support Year
2
Fiscal Year
1992
Total Cost
Indirect Cost
Name
Emory University
Department
Type
Schools of Arts and Sciences
DUNS #
042250712
City
Atlanta
State
GA
Country
United States
Zip Code
30322
Abobo, C V; Ni, L; Schinazi, R F et al. (1994) Pharmacokinetics of 2',3'-dideoxy-5-fluoro-3'-thiacytidine in rats. J Pharm Sci 83:96-9